Results 41 to 50 of about 5,967 (167)

NTRK Fusions in 1113 Solid Tumors in a Single Institution

Diagnostics, 2022
Most NTRK fusions occur at very low frequencies in various common cancers. Recent recommendations on NTRK testing recommend immunohistochemistry (IHC) as the initial test for tumor types with a low frequency of NTRK fusions. This study investigated the accuracy of an IHC assay to detect NTRK fusions and characterize the clinicopathological and ...
Heejin Bang, Mi-Sook Lee, Minjung Sung, Juyoung Choi, Sungbin An, Seok-Hyung Kim, Seung Eun Lee, Yoon-La Choi   +7 more
openaire   +3 more sources

Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report

Case Reports in Oncology, 2021
While neurotrophic tropomyosin receptor kinase (NTRK) fusions represent rare oncogenic drivers (<1% of solid cancers), the recent approval of NTRK inhibitors (larotrectinib and entrectinib) led to dramatic responses in patients with NTRK fusion ...
Tyler Lanman, Melanie Hayden Gephart, Nam Bui, Angus Toland, Seema Nagpal   +4 more
doaj   +1 more source

Analysis of NTRK mutation and clinicopathologic factors in lung cancer patients in northeast China

The International Journal of Biological Markers, 2020
Objective: NTRK mutations and clinicopathological factors in patients with lung cancer in northeast China were analyzed by next-generation sequencing (NGS), and references were provided for patients with NTRK mutations undergoing targeted therapy in ...
Hui Li, Shi Yan, Ying Liu, Lixia Ma, Xianhong Liu, Yan Liu, Ying Cheng   +6 more
doaj   +1 more source

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance

Respirology Case Reports, 2022
Acquired resistance to osimertinib is inevitable and heterogeneous despite its documented efficacy against EGFR‐mutated non‐small cell lung cancer (NSCLC).
Jiao‐Li Wang, Liu‐sheng Wang, Jun‐qi Zhu, Jie Ren, Di Wang, Man Luo   +5 more
doaj   +1 more source

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

Frontiers in Oncology, 2022
Rearrangements involving the neurotrophin kinase (NTRK) genes NTRK1, NTRK2 and NTRK3 with different fusion partners have been observed in both adult and pediatric solid tumors.
Chiara Lazzari, Lorenza Pecciarini, Claudio Doglioni, Federica Pedica, Ana Maria Samanes Gajate, Alessandra Bulotta, Vanesa Gregorc, Maria Giulia Cangi   +7 more
doaj   +1 more source

Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours

Scientific Reports, 2023
NTRK gene fusions are rare somatic mutations found across cancer types with promising targeted therapies emerging. Healthcare systems face significant challenges in integrating these treatments, with uncertainty in prevalence and optimal testing methods ...
Sophie O’Haire, Fanny Franchini, Yoon-Jung Kang, Julia Steinberg, Karen Canfell, Jayesh Desai, Stephen Fox, Maarten IJzerman   +7 more
doaj   +1 more source

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib

Frontiers in Oncology, 2023
Pancreatic neuroendocrine carcinoma (panNEC) is a rare disease. The rearrangements of neurotrophic tropomyosin receptor kinase (NTRK) genes are oncogenic.
Wen-Chi Wu, Wen-Chi Wu, Wen-Chi Wu, Wen-Chi Wu, Ming-Huang Chen, Ming-Huang Chen, Ming-Huang Chen   +6 more
doaj   +1 more source

Oncogenic fusions: Targeting NTRK

Critical Reviews in Oncology/Hematology
Non-Small Cell Lung Cancer (NSCLC) is responsible for the highest number of cancer-related deaths in the United States. Thankfully, advancements in the detection and targeting of gene mutations have greatly improved outcomes for many patients. One significant mutation driving oncogenesis in various cancers, including NSCLC, is the neurotrophic tyrosine
Garo Hagopian, Misako Nagasaka
openaire   +2 more sources

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC

JTO Clinical and Research Reports, 2023
Introduction: Gene fusion testing of ALK, ROS1, RET, NTRK, and MET exon 14 skipping mutations is guideline recommended in nonsquamous NSCLC (NS-NSCLC).
Véronique Hofman, MD, PhD, Simon Heeke, PhD, Christophe Bontoux, MD, Lara Chalabreysse, MD, Marc Barritault, MD, PhD, Pierre Paul Bringuier, DVM, Tanguy Fenouil, MD, PhD, Nazim Benzerdjeb, MD, PhD, Hugues Begueret, MD, PhD, Jean Philippe Merlio, MD, PhD, Charline Caumont, MD, Nicolas Piton, MD, PhD, Jean-Christophe Sabourin, MD, PhD, Solène Evrard, MD, PhD, Charlotte Syrykh, MD, Anna Vigier, MD, Pierre Brousset, MD, PhD, Julien Mazieres, MD, PhD, Elodie Long-Mira, MD, PhD, Jonathan Benzaquen, MD, PhD, Jacques Boutros, MD, Maryline Allegra, PhD, Virginie Tanga, MSc, Virginie Lespinet-Fabre, PhD, Myriam Salah, MSc, Christelle Bonnetaud, MSc, Olivier Bordone, MSc, Sandra Lassalle, MD, PhD, Charles-Hugo Marquette, MD, PhD, Marius Ilié, MD, PhD, Paul Hofman, MD, PhD   +30 more
doaj   +1 more source

NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome

JCO Precision Oncology, 2021
PURPOSE Neurotrophic tyrosine receptor kinase (NTRK) fusions have been described as oncogenic drivers in a variety of tumors. However, little is known about the overall frequency of NTRK fusion in unselected pediatric tumors. Here, we assessed the frequency, fusion partners, and clinical course in pediatric patients with NTRK fusion–positive tumors ...
Zhao, Xiaonan, Kotch, Chelsea, Fox, Elizabeth, Surrey, Lea F., Wertheim, Gerald B., Baloch, Zubair W., Lin, Fumin, Pillai, Vinodh, Luo, Minjie, Kreiger, Portia A., Pogoriler, Jennifer E., Linn, Rebecca L., Russo, Pierre A., Santi, Mariarita, Resnick, Adam C., Storm, Phillip B., Hunger, Stephen P., Bauer, Andrew J., Li, Marilyn M.   +18 more
openaire   +2 more sources